Italfarmaco, Luye enter commercialization pact for transdermal alzheimers treatment

Italfarmaco Group and Luye Pharma announced today that they entered into a commercialization agreement for Rivastigmine MD.

Under the agreement, Milan, Italy-based Italfarmco receives exclusive rights to commercialize the Rivastigmine multi-day transdermal patch in four European companies, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0